Association Between Low Trough Levels of Vedolizumab During Induction Therapy for Inflammatory Bowel Diseases and Need for Additional Doses Within 6 Months

Clinical Gastroenterology and Hepatology

Volumn 15, Issue 11, 2017, Pages 1750-1757.e3

  Williet, Nicolas ^a   Boschetti, Gilles ^b,c   Fovet, Marion ^a   Di Bernado, Thomas ^a   Claudez, Pierre ^a   Del Tedesco, Emilie ^a   Jarlot, Camille ^a   Rinaldi, Leslie ^a   Berger, Anne ^d,e   Phelip, Jean Marc ^a   Flourie, Bernard ^b,c   Nancey, Stéphane ^b,c   Paul, Stéphane ^d,e   Roblin, Xavier ^a,e  

^a UNIVERSITÉ JEAN MONNET   (France)

^b CENTRE HOSPITALIER LYON SUD   (France)

^c CENTRE INTERNATIONAL DE RECHERCHE EN INFECTIOLOGIE   (France)

^d UNIVERSITY HOSPITAL OF SAINT ETIENNE   (France)

^e UNIVERSITÉ LYON 1   (France)

Author keywords

Drug; IBD; Optimization of Treatment; Patient Management

Indexed keywords

ALPHA4 INTEGRIN; BETA INTEGRIN; VEDOLIZUMAB; GASTROINTESTINAL AGENT; MONOCLONAL ANTIBODY;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; CROHN DISEASE; DRUG BLOOD LEVEL; DRUG RESPONSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MALE; MEASUREMENT ACCURACY; MINIMUM PLASMA CONCENTRATION; OBSERVATIONAL STUDY; PREDICTIVE VALUE; PROCESS OPTIMIZATION; RECEIVER OPERATING CHARACTERISTIC; REMISSION; SCORING SYSTEM; TREATMENT DURATION; ULCERATIVE COLITIS; CHEMISTRY; FRANCE; INDUCTION CHEMOTHERAPY; INFLAMMATORY BOWEL DISEASE; MIDDLE AGED; PROSPECTIVE STUDY; SERUM; TIME FACTOR;

ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; FEMALE; FRANCE; GASTROINTESTINAL AGENTS; HUMANS; INDUCTION CHEMOTHERAPY; INFLAMMATORY BOWEL DISEASES; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SERUM; TIME FACTORS;

EID: 85032913135     PISSN: 15423565     EISSN: 15427714     Source Type: Journal    
DOI: 10.1016/j.cgh.2016.11.023     Document Type: Article

References (11)

1. Commissioner of the United Food Administration. FDA approves Entyvio to treat ulcerative colitis and Crohn's disease. Available at: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm398065.htm. Accessed May 17, 2016.
2. European Medicines Agency - Find medicine - Entyvio. Available at: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002782/human_med_001751.jsp&mid=WC0b01ac058001d124. Accessed May 17, 2016.
3. Sandborn, W.J., Feagan, B.G., Rutgeerts, P., et al. Vedolizumab as induction and maintenance therapy for Crohn's disease. N Engl J Med 369 (2013), 711–721.
4. Feagan, B.G., Rutgeerts, P., Sands, B.E., et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med 369 (2013), 699–710.
5. Lam, M.C., Bressler, B., Vedolizumab for ulcerative colitis and Crohn's disease: results and implications of GEMINI studies. Immunotherapy 6 (2014), 963–971.
6. Paul, S., Del Tedesco, E., Marotte, H., et al. Therapeutic drug monitoring of infliximab and mucosal healing in inflammatory bowel disease: a prospective study. Inflamm Bowel Dis 19 (2013), 2568–2576.
7. Roblin, X., Rinaudo, M., Del Tedesco, E., et al. Development of an algorithm incorporating pharmacokinetics of adalimumab in inflammatory bowel diseases. Am J Gastroenterol 109 (2014), 1250–1256.
8. Williet, N., Paul, S., Peyrin-Biroulet, L., et al. Pharmacokinetics of infliximab and reduction of treatment for inflammatory bowel diseases. Dig Dis Sci 61 (2016), 990–995.
9. Silverberg, M.S., Satsangi, J., Ahmad, T., et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol J Can Gastroenterol 19:Suppl A (2005), 5A–36A.
10. Parikh, A., Leach, T., Wyant, T., et al. Vedolizumab for the treatment of active ulcerative colitis: a randomized controlled phase 2 dose-ranging study. Inflamm Bowel Dis 18 (2012), 1470–1479.
11. Brandse, J.F., van den Brink, G.R., Wildenberg, M.E., et al. Loss of infliximab into feces is associated with lack of response to therapy in patients with severe ulcerative colitis. Gastroenterology 149 (2015), 350–355.